Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
December 18, 2019 17:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment
November 13, 2018 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours
November 05, 2018 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
October 01, 2018 07:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
July 25, 2018 12:53 ET
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board
May 15, 2018 13:34 ET
|
Qu Biologics
VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
April 18, 2018 16:16 ET
|
Qu Biologics
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique...
Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress
December 19, 2017 12:45 ET
|
Qu Biologics
VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer
November 28, 2017 12:43 ET
|
Qu Biologics
VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...